Home » NABI BIOPHARMA CLOSES EUROPEAN OPERATIONS
NABI BIOPHARMA CLOSES EUROPEAN OPERATIONS
Biotech company Nabi Biopharmaceuticals said Monday it closed its European operations to cut expenses, as it assesses the results of late-stage trial of its experimental staph infection vaccine, StaphVax. The company said in November -- after the product's Phase III clinical trial failed to reduce infections in a kidney patient study -- that it was withdrawing its marketing authorization application in Europe. The company said the closing of its operations in Europe is in line with that decision.
MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051219&ID=5366484)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May